Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience Corporation held its 2026 Annual Meeting of Stockholders, with strong participation from holders of 56,260,506 common shares, representing about 91.81% of shares eligible to vote. This high turnout indicates that most stockholders were represented, either in person or by proxy.
Stockholders elected three Class II directors to three-year terms: Keith Crandell, Jan Johannessen, and Trynka Shineman Blake. Blake received 50,217,493 votes for and 88,210 votes withheld, while Crandell and Johannessen each also secured substantial majorities, ensuring continuity on the board.
Investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 38,430,673 votes for, 11,842,367 against, and 32,663 abstentions, along with 5,954,803 broker non-votes. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with 56,220,551 votes for, 18,170 against, and 21,785 abstentions.
A holder of the issuer’s common stock has filed a Form 144 notice to sell up to 2,200 common shares through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $105,394.74, around February 6, 2026.
The 2,200 shares were acquired on February 5, 2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, the same holder sold 7,044 common shares on November 18, 2025 for gross proceeds of $174,479.88.
Twist Bioscience Corp's President and COO, Patrick John Finn, reported an automatic sale of common stock tied to equity compensation. On 02/03/2026, 2,705 shares of common stock were sold at $46.576 per share to cover tax withholding obligations from vesting restricted stock units. After this mandated "sell to cover" transaction under the company’s equity incentive plans, Finn beneficially owned 307,788 shares of Twist Bioscience common stock.
Twist Bioscience executive Dennis Cho reported a routine tax-related stock sale. On February 3, 2026, he sold 1,099 shares of Twist Bioscience common stock at $46.576 per share to cover tax withholding from vesting restricted stock units under the company’s equity plans.
After this mandated “sell to cover” transaction, Cho beneficially owned 143,581 shares of common stock in direct ownership. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and the filing notes these were not discretionary trades.
Twist Bioscience Corp’s Chief Executive Officer and director Emily M. Leproust reported an automatic sale of common stock tied to equity compensation. On February 3, 2026, she sold 5,001 shares of common stock at $46.576 per share in a transaction coded “S.”
The filing explains these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans, described as a mandatory “sell to cover” and not a discretionary trade. After this sale, Leproust beneficially owned 869,312 shares of Twist Bioscience common stock and continued to hold various employee stock options, including 64,950 performance stock options that vested after meeting performance criteria in December 2022.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported mandatory sales of common stock to cover taxes on vested restricted stock units. On February 3, 2026, he sold 175 shares at $46.576 per share. On February 4, 2026, he sold an additional 7,000 shares at a weighted average price of $45.648 per share, with actual sale prices ranging from $45.61 to $45.78. These "sell to cover" transactions were required under the company’s equity incentive plan and are described as non-discretionary. After these transactions, Werner directly owned 58,738 shares of Twist Bioscience common stock.
Twist Bioscience Corporation reported that SVP of Human Resources Paula Green sold 1,194 shares of common stock on February 3, 2026 at $46.576 per share. After this transaction, she directly holds 165,445 shares.
The sale was a mandatory “sell to cover” transaction to satisfy tax withholding owed on vesting restricted stock units, under the company’s equity incentive plan, and was not a discretionary trade by the executive.
Robert F. Werner has filed a notice of proposed sale of 7,000 common shares, with an aggregate market value of $319,532.51, to be sold through Fidelity Brokerage Services LLC on NASDAQ around 02/04/2026. The filing lists 61,311,704 common shares outstanding.
The 7,000 shares come from restricted stock that vested as compensation between 05/22/2024 and 02/02/2025, in multiple smaller tranches. The notice also reports past three-month sales by Werner totaling 1,456 shares across four transactions, with disclosed gross proceeds for each sale.
Patrick Finn has filed notice to sell 2,705 shares of common stock of TWST on or about 02/03/2026 through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $125,986.73.
The shares to be sold were acquired on 02/02/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, Finn reported several sales of TWST common stock, including 23,279 shares on 01/13/2026 for $931,160.00 and 2,390 shares on 01/23/2026 for $107,329.41.
A shareholder of TWST has filed a Rule 144 notice to sell 175 shares of common stock on the NASDAQ through Fidelity Brokerage Services, with an approximate sale date of February 3, 2026.
The 175 shares were acquired on February 2, 2026 through restricted stock vesting from the issuer as compensation. The filing also lists recent sales for the same seller, including 160 common shares sold on November 3, 2025 for $5,132.70 and 822 common shares sold on November 24, 2025 for $23,599.21. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.